Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood–brain barrier and target glioma

Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood–brain barrier and target glioma

Abstract In 2009, the FDA approved bevacizumab for the treatment of adult patients diagnosed with recurrent glioblastoma. However, the poor permeability of the macromolecules across the blood–brain barrier, determined by multifactorial anatomical and physiological milieu, restricts the clinical ther...

Full description

Bibliographic Details
Main Authors: Xuemei Ji, Hongyan Wang, Yue Chen, Junfei Zhou, Yu Liu
Format: Article
Language:English
Published: SpringerOpen 2019-10-01
Series:AMB Express
Subjects:
Glioma
Blood–brain barrier
Angiopep-2
ScFab-ANG
Transepithelial permeability
Online Access:http://link.springer.com/article/10.1186/s13568-019-0869-3

Internet

http://link.springer.com/article/10.1186/s13568-019-0869-3

Similar Items